Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
TriSalus Life Sciences ( (TLSI) ) has issued an announcement.
On February 9, 2026, TriSalus Life Sciences announced changes to its Board of Directors, reflecting ongoing evolution in its governance as it advances its oncology-focused medical technology platform. The company, which develops proprietary Pressure-Enabled Drug Delivery (PEDD) devices and an investigational immunotherapy to improve treatment of solid tumors in the liver and pancreas, is aligning its leadership with its growth and clinical development objectives.
The company reported that Dr. Arjun “JJ” Desai, who had served on the Board since August 2023, resigned from the Board, with TriSalus publicly recognizing his contributions during a critical phase of its development. Effective February 4, 2026, veteran healthcare investor Michael P. Stansky was appointed to the Board, bringing four decades of investment management and healthcare experience, which TriSalus expects will strengthen its capital markets expertise, governance capabilities, and support for long-term value creation for shareholders.
The most recent analyst rating on (TLSI) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on TriSalus Life Sciences stock, see the TLSI Stock Forecast page.
Spark’s Take on TLSI Stock
According to Spark, TipRanks’ AI Analyst, TLSI is a Neutral.
TriSalus Life Sciences’ overall stock score is driven by significant financial challenges, including persistent losses and a weak balance sheet, which weigh heavily on the score. However, strong technical indicators and positive earnings call sentiment, highlighting revenue growth and strategic expansion, provide some optimism. The negative P/E ratio and lack of dividend yield further constrain the valuation score.
To see Spark’s full report on TLSI stock, click here.
More about TriSalus Life Sciences
TriSalus Life Sciences, Inc. is an oncology-focused medical technology company developing novel drug delivery technologies integrated with standard-of-care therapies to improve outcomes for patients with solid tumors. Its platform combines FDA-cleared devices using proprietary Pressure-Enabled Drug Delivery (PEDD) technology, such as the TriNav Infusion Systems for liver tumors and the Pancreatic Retrograde Venous Infusion System, with its clinical-stage investigational immunotherapy nelitolimod, targeting the immunosuppressive tumor microenvironment in organs like the liver and pancreas.
The company’s PEDD approach is designed to modulate pressure and flow to deliver higher concentrations of therapeutics directly to tumors while limiting exposure to healthy tissue, potentially enhancing the effectiveness of treatments. TriSalus is in the final stages of data completion for several phase 1 clinical trials evaluating nelitolimod delivered via PEDD and plans to explore partnership opportunities for further development, aiming to expand its impact across multiple cancer types where TLR9 is expressed and mechanical barriers are similar.
Average Trading Volume: 167,884
Technical Sentiment Signal: Sell
Current Market Cap: $237.3M
For an in-depth examination of TLSI stock, go to TipRanks’ Overview page.